Figure 1.

Blood eosinophil count (thin transparent lines for individual data, thick lines with markers for geometric group mean, and error bars represent 95% confidence intervals for geometric mean) on logarithmic scale before and after treatment with mepolizumab (100 mg s.c.), benralizumab (30 mg s.c.), or oral prednisolone (30 mg). There was a statistically significant change (P < 0.05 using repeated-measures ANOVA and least significant difference post hoc test) from baseline at 2 and 4 hours in the benralizumab arm, at 4 hours in the prednisolone arm, and from 24 hours onward in the mepolizumab arm. There was no significant difference between the treatment arms at baseline, but the mepolizumab arm differed significantly from benralizumab arm at 2 and 4 hours and 30 days and from prednisolone arm at 4 hours (ANOVA with least significant difference post hoc test).